$ARE Alexandria Real Estate is the best positioned REITs for the upcoming Biotech recovery

https://preview.redd.it/unc0ga4wwsyg1.png?width=1080&format=png&auto=webp&s=0252881ac63aa507331b829c937ac1de5f3124ba

Alexandria Real Estate is the best positioned REITs for the upcoming Biotech recovery and 90% of the market and analysts are completely missing it. I'm just posting this for posterity and to use this as a reference in some number of months or years. I don't expect many people at all to read this or agree with me since there are many other exciting opportunities on the market. But I fully expect this to outperform the market greatly in the years to come.

Context

Some background is that $ARE is the premier life science REIT and is widely known in the US as the most trustworthy, experienced, and optimized landlord and developer for life science (biotech) real estate. Virtually every single big pharma company has major leases with them extending many years to even decades into the future. Their main strategy has proven to outperform broader leasing the market significantly and it seems to only be getting better with time. That strategy being developing A class lab space in key city centers near hospitals, universities, downtowns and other major institutes, they call these clusters. Increasingly tenants are moving towards these clusters and are willing to pay increased prices for these spots. The company is going through dispositions to sell property that is not in these key centers in order to fund development in these centers.

Thesis

Alexandria Real Estate Equities is an extremely beat down REIT that fell from grace as a blue chip wonder child to currently being valued with multiples less than some of the worst tier REITs. The reason for this fall is multi faceted but there are undeniably good reasons as to why the market has sold off which I will provide context for. At the moment it is sitting at 15 year lows and is down almost 80% in the last 5 years. At it's recent peak in 2021 it was in an optimal market for life science but since then biotech has slowed since the covid boom, and the company is dealing with major headwinds such as government friction (NIH, FDA turmoil with their tenants), tighter capital markets, and oversupply of lab space. However valid these concerns are, they are currently bleeding into an overextended sell off that has no fundamentals justifying such a steep sell off, and one which has a lot of potential for a large run up on any good news or catalyst, of which there are many.

• Numbers: First let's get into the numbers of it to highlight the divergence
  • Let's look at the asset values, as you can see below when calculating the value of the stock purely from a book value (aka how much are all there assets worth if you liquidated them) the price is nearly 3X what the stock is trading for now. Even if you assign an extraordinarily bearish multiplier and assume the real value of their assets is 50% less than the value (which is a nigh impossibility in accounting) then the NAV would still be worth nearly $60 which is

• Next lets look at a key metric for REITs P/FFO, which is the ratio of price to funds from operation. It's a standard that many analysts use to project fair value for a company based on how much money they can generate from operations (leases). Typically for REITs a relatively standard P/FFO is 9-10X. And for Alexandria the historical average has been around 18-25X. A distressed REIT that is on the verge of bankruptcy usually sits around 4-6X. Currently Alexandria is sitting at it's lowest multiple ever around 6X even though it currently has $5 billion in liquid cash and infinite options in terms of levers it can pull to stretch operations indefinitely. Any analysis of the companies financials will show that the risk of bankruptcy is essentially 0%. In fact based on the company's long history and ability to whether major market downturns including early 2000s and 2008 shows that the company is not only resilient but very well prepared and equipped to smartly handle challenges. A return to 18-25X P/FFO is very possible in the coming years which would yield a 3-4X return, similar to the NAV estimates above. The main problem is that P/FFO is contingent on both current performance and future expected performance/growth. It may take some time for the narrative of growth to return to the battered field, but as a cyclical industry it will surely return. Even a modest P/FFO growth to 9-12X would result in more than 50% gain in stock price.
• The dividend was a huge reason for the sell off and why the stock price continues to be suppressed, many people and funds bought into the stock with the expectation that it would be a dividend printer, and many funds were forced to sell their positions legally after the yield dropped below their contractual agreements with their investors. The dividend was cut nearly 45% but still sits at around a 7% yield which is extremely healthy for investors, and also sustainable for the company. The 7% annual yield will definitely help bolster the opportunity cost of holding.
• Leasing Activity and Future Positioning
  • Now that we looked at the raw numbers and substantiated that on paper the company seems very fundamentally strong but oversold lets walk through the companies core business.
  • The main and obvious reason that the company fell is due to a drop in leasing activity due to previously mentioned market headwinds in biotech, with occupancy rates falling from 96% to 87% in the last couple of years. Currently since there has been no reported rebound yet the bottom is still not officially in and people are waiting for a clear turnaround catalyst before buying. I will also mention that the occupancy rate has a strong floor due to big pharma companies renting a large majority of spaces with 7+ year long leases. However I think everyone can understand that real estate is a lagging indicator and usually leases are the last place to show growth from macro conditions. Let's see some signs that the biotech market is recovering (Biotech was in a bear phase from 2022-2025).
    • Key biotech index $XBI is up 55.94% in the last year, significantly outperforming the market by more than 2X.
    • 6 Biotech IPOs in 2026 Q1 raising $1.8 billion vs in 2025 where the entire year only raised $1.6 billion across all 4 quarters combined
  • Other Catalysts:
    • Advanced Technology leases are being made which will help reduce oversupply and fill in occupancy. They company is working with tenants like Amazon, Google, Meta, etc to fill in lab space in sites like SF, Boston and SD. These companies often need non traditional office space with more open floor plans, high ceiling, access to higher wattage, and wet/dry labs. This seems to be a huge new direction they are exploring. They also feel quite bullish about AI integration in biotech research and cite it as a growth driver not a replacement for lab space. Keep in mind 100,000 sqft of lab space can only accomodate around 300 biotech employees, and no firms have cited AI as reducing the need for space, only for increasing the need, so it seems increasingly untrue that AI can or will displace the need for biotech workers or space.
    • Change in Government Policy, especially towards NIH, FDA and other health agencies will undeniably help continue to help biotech re-ramp up from its bear phase. Likely midterms will help push some of these changes and possibly introduce new legislation that is supportive or protective of biotech research which is a key industry on the global market and critical for US hegemony.
    • This is a huge one, but there is currently a $2.9 billion disposition plan to sell about 10% of the company's non core assets. This is good in many ways because it helps reduce capital expenditure of maintaining non premium buildings, and frees up undeveloped land to be reallocated to other uses while the company focuses on their clusters. It also gives the company a ton of cash to run operations, pay dividend etc. But I think the most important aspect of this disposition plan that people don't see is that if it goes through then this reinforces the previous NAV. $2.9 Billion * 10 = $29 billion in real estate asset values. This would concretely prove their portfolios book value is far higher than any analyst wants to give them credit for right now and would essentially double their market cap. $29 Billion – 14 Billion in debt = $15 Billion vs current market cap of $7 Billion.
    • Oversupply in lab space is decreasing as 2025 and 2026 has virtually no new developments for biotech labs. These developments span many years (3-5+) to ramp up, so the fact that there is a wind down now means that the current inventory is static if not decreasing since many older buildings across the market will be sunset due to age, especially in this tight market. Additionally oversupply is being handled internally with pivoting to advanced technology leases as state above.
• Price Predictions
  • Now let's get into the fun part of throwing out some predictions for the price. Based on the numbers I listed above it seems like a full bullish recovery of the biotech market will lead to a return to $120+ price point. It seems like a lukewarm recovery to basic valuation will lead to $60-80 price point. And it seems very unlikely that the stock can sell off much further than $40 due to the math that I mentioned, and the fact that the dividend yield can only be so high before funds will auto buy.
  • My Position: ~$700,000 @ $41 average